Stuart C. Gordon
#187,631
Most Influential Person Across History
Stuart C. Gordon's AcademicInfluence.com Rankings
Download Badge
Physics
Stuart C. Gordon's Degrees
- Bachelors Physics Stanford University
Why Is Stuart C. Gordon Influential?
(Suggest an Edit or Addition)Stuart C. Gordon's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial (2001) (6290)
- Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. (1998) (3524)
- Sofosbuvir for previously untreated chronic hepatitis C infection. (2013) (1815)
- Boceprevir for previously treated chronic HCV genotype 1 infection. (2011) (1711)
- Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. (1998) (1334)
- Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. (2014) (1329)
- Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. (2014) (1153)
- Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. (2013) (1122)
- Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. (2009) (905)
- Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. (2015) (764)
- Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial (2010) (733)
- A randomized, double‐blind trial comparing pegylated interferon alfa‐2b to interferon alfa‐2b as initial treatment for chronic hepatitis C (2001) (651)
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial (2019) (620)
- Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. (2015) (466)
- Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. (2018) (457)
- Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection (2017) (452)
- Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. (2007) (450)
- Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. (2004) (442)
- Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. (2005) (380)
- All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study (2014) (342)
- Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. (2004) (337)
- Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial (2013) (315)
- A Randomized , Double-Blind Trial Comparing Pegylated Interferon Alfa-2 b to Interferon Alfa-2 b as Initial Treatment for Chronic Hepatitis C (2001) (273)
- Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. (2017) (267)
- Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection (2010) (251)
- Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. (2016) (211)
- Factors that predict response of patients with hepatitis C virus infection to boceprevir. (2012) (209)
- The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. (2000) (201)
- Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C (2003) (197)
- Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. (2012) (175)
- Serum Ferritin Level Predicts Advanced Hepatic Fibrosis among U.S. Patients with Phenotypic Hemochromatosis (2003) (175)
- Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment (2017) (174)
- Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. (2015) (171)
- The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. (2015) (169)
- Baseline characteristics and mortality among people in care for chronic viral hepatitis: the chronic hepatitis cohort study. (2013) (159)
- Hepatitis C Guidance 2019 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. (2019) (158)
- Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. (2015) (147)
- The pathology of hepatitis C as a function of mode of transmission: Blood transfusion vs. Intravenous drug use (1993) (135)
- Prolonged intrahepatic cholestasis secondary to acute hepatitis A. (1984) (133)
- Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006-2010. (2015) (133)
- Clinical outcome of hepatitis C as a function of mode of transmission (1998) (132)
- Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. (2016) (129)
- Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort. (2013) (129)
- Phase 1B, randomized, double‐blind, dose‐escalation trial of CPG 10101 in patients with chronic hepatitis C virus (2007) (127)
- High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis. (2018) (127)
- Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population. (2014) (123)
- A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. (2014) (118)
- Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure (2018) (116)
- Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection (2012) (110)
- Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C (1998) (110)
- Cryptogenic liver disease in the United States: further evidence for non-A, non-B, and non-C hepatitis. (1994) (107)
- Resolution of a contraceptive-steroid-induced hepatic adenoma with subsequent evolution into hepatocellular carcinoma. (1986) (106)
- Antibodies to carbonic anhydrase in patients with immune cholangiopathies. (1995) (106)
- Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load (2013) (106)
- Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. (2017) (104)
- Cost-effectiveness of screening for chronic hepatitis C infection in the United States. (2011) (103)
- Fibrosis heterogeneity in nonalcoholic steatohepatitis and hepatitis C virus needle core biopsy specimens. (2005) (102)
- Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. (2015) (98)
- Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection. (2012) (97)
- Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE. (2016) (97)
- 4 HCV SPRINT-1 FINAL RESULTS: SVR 24 FROM A PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRON™ (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT- NAIVE SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C (2009) (84)
- The Burden of Acute Nonfulminant Drug-induced Hepatitis in a United States Tertiary Referral Center (2005) (82)
- Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials (2015) (82)
- IL28B Polymorphism Predicts Virologic Response in Patients With Hepatitis C Genotype 1 Treated With Boceprevir (Boc) Combination Therapy (2011) (81)
- Lack of evidence for the heterosexual transmission of hepatitis C. (1992) (80)
- Minocycline as a cause of drug-induced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis. (2000) (79)
- The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C (2000) (78)
- 12 IL28B POLYMORPHISM PREDICTS VIROLOGIC RESPONSE IN PATIENTS WITH HEPATITIS C GENOTYPE 1 TREATED WITH BOCEPREVIR (BOC) COMBINATION THERAPY (2011) (78)
- Long‐term clearance of hepatitis C virus following interferon α‐2b or peginterferon α‐2b, alone or in combination with ribavirin (2013) (77)
- The spectrum of liver disease in the acquired immunodeficiency syndrome. (1986) (77)
- Predictors of poor mental and physical health status among patients with chronic hepatitis C infection: The Chronic Hepatitis Cohort Study (CHeCS) (2015) (76)
- Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. (2013) (75)
- 2 FARNESOID-X RECEPTOR AGONISTS: A NEW CLASS OF DRUGS FOR THE TREATMENT OF PBC? AN INTERNATIONAL STUDY EVALUATING THE ADDITION OF INT-747 TO URSODEOXYCHOLIC ACID (2010) (73)
- Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment (2001) (73)
- Genetic polymorphisms of toll-like receptor 9 influence the immune response to CpG and contribute to hyper-IgM in primary biliary cirrhosis. (2005) (73)
- Epigenetic investigation of variably X chromosome inactivated genes in monozygotic female twins discordant for primary biliary cirrhosis (2011) (73)
- Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data (2020) (68)
- Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment (2017) (66)
- Serum alpha-fetoprotein levels in patients with chronic hepatitis C. Relationships with serum alanine aminotransferase values, histologic activity index, and hepatocyte MIB-1 scores. (1999) (63)
- The effect of catheter-directed CT angiography on yttrium-90 radioembolization treatment of hepatocellular carcinoma. (2005) (61)
- All-Cause Mortality and Progression Risks to Hepatic Decompensation and Hepatocellular Carcinoma in Patients Infected With Hepatitis C Virus. (2016) (60)
- All-Cause Mortality and Progression Risks to Hepatic Decompensation and Hepatocellular Carcinoma in Patients Infected With Hepatitis C Virus. (2016) (60)
- Genome-Wide Analysis of DNA Methylation, Copy Number Variation, and Gene Expression in Monozygotic Twins Discordant for Primary Biliary Cirrhosis (2014) (60)
- Advancing Age and Comorbidity in a US Insured Population‐Based Cohort of Patients With Chronic Hepatitis B (2019) (57)
- Extrahepatic manifestations of hepatitis C. (1996) (57)
- Levels of hepatitis C virus RNA and liver histology in chronic type C hepatitis. (1994) (57)
- Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. (2018) (57)
- 4 PROVE1: RESULTS FROM A PHASE 2 STUDY OF TELAPREVIR WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH HEPATITIS C (2008) (57)
- Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial. (2016) (54)
- Risk for Renal Cell Carcinoma in Chronic Hepatitis C Infection (2010) (53)
- 104 BOCEPREVIR (B) COMBINATION THERAPY IN NULL RESPONDERS (NR): RESPONSE DEPENDENT ON INTERFERON RESPONSIVENESS (2008) (53)
- 995 INTERIM RESULTS FROM HCV SPRINT-1: RVR/EVR FROM PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRONTM (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE-1 CHC (2008) (51)
- Sequential serum hepatitis C viral RNA levels longitudinally assessed by branched DNA signal amplification (1998) (50)
- 751 The safety and efficacy of viramidine® plus pegylated interferon alpha-2B versus ribavirin plus pegylated interferon alpha-2B in therapy-naïve patients infected with HCV: Phase 3 results (2006) (50)
- Celecoxib-induced cholestatic hepatitis. (2001) (50)
- No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients. (2018) (49)
- Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy‐proven histological damage (2010) (49)
- Clinical assessment for high‐risk patients with non‐alcoholic fatty liver disease in primary care and diabetology practices (2020) (48)
- 1360 PEGYLATED INTERFERON-LAMBDA (PEGIFN-λ) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFNα-2A IN HCV PATIENTS (Gl/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12 (2011) (48)
- Phase 1 b Study of Pegylated Interferon Lambda 1 With or Without Ribavirin in Patients with Chronic Genotype 1 Hepatitis C Virus Infection (2010) (46)
- Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. (2014) (45)
- Prolonged Intrahepatic Cholestasis and Renal Failure Secondary to Anabolic Androgenic Steroid-Enriched Dietary Supplements (2009) (45)
- Serum Biomarkers Indicate Long-term Reduction in Liver Fibrosis in Patients With Sustained Virological Response to Treatment for HCV Infection. (2016) (44)
- Late diagnosis of hepatitis C virus infection in the Chronic Hepatitis Cohort Study (CHeCS): Missed opportunities for intervention (2015) (43)
- Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health Systems (2017) (41)
- 11 SUSTAINED VIROLOGIC RESPONSE (SVR) IN PRIOR PEGINTERFERON/RIBAVIRIN (PR) TREATMENT FAILURES AFTER RETREATMENT WITH BOCEPREVIR (BOC)-+-PR: THE PROVIDE STUDY INTERIM RESULTS (2012) (41)
- Differences in Hepatic Phenotype Between Hemochromatosis Patients With HFE C282Y Homozygosity and Other HFE Genotypes (2009) (41)
- Assessment of hepatitis B virus DNA and hepatitis C virus RNA in the common bedbug (Cimex lectularius L.) and kissing bug (Rodnius prolixus). (2001) (40)
- Relationships between Hepatic Iron Content and Virologic Response in Chronic Hepatitis C Patients Treated with Interferon and Ribavirin (2005) (39)
- Prevalence of Cirrhosis in Hepatitis C Patients in the Chronic Hepatitis Cohort Study (CHeCS): A Retrospective and Prospective Observational Study (2015) (39)
- Pegylated interferon alfa-2B (PEG-intron) mono-therapy is superior to interferon alfa-2B (intron A) for the treatment of chronic hepatitis C (2000) (38)
- Infrequent Clinical Assessment of Chronic Hepatitis B Patients in United States General Healthcare Settings. (2016) (38)
- Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States (2016) (37)
- Mumps arthritis: a review of the literature. (1984) (37)
- Mumps arthritis: unusual presentation as adult Still's disease. (1982) (37)
- Assessment of hepatitis B virus DNA and hepatitis C virus RNA in the common bedbug (Cimex lectularius L.) and kissing bug (Rodnius prolixus) (2001) (36)
- Uptake of and Factors Associated With Direct-acting Antiviral Therapy Among Patients in the Chronic Hepatitis Cohort Study, 2014 to 2015 (2017) (35)
- Antiviral Activity of ANA773, an Oral Inducer of Endogenous Interferons that Acts Via TLR7, in Chronic Hepatitis C Patients (2011) (35)
- Hepatitis C treatment failure is associated with increased risk of hepatocellular carcinoma (2016) (34)
- Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics. (2013) (33)
- Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes (2019) (33)
- Alfa interferon treatment of hepatitis C virus RNA-positive patients with normal or near-normal alanine aminotransferase levels. (1997) (32)
- Evaluation of anti-HBV drug resistant mutations among patients with acute symptomatic hepatitis B in the United States. (2013) (31)
- High Efficacy of Abt-493 and Abt-530 in Hcv Genotype 1 Infected Patients who Have Failed Direct-Acting Antiviral-Containing Regimens: The Magellan-I Study (2016) (30)
- Portal tract eosinophils and hepatocyte cytokeratin 7 immunoreactivity helps distinguish early-stage, mildly active primary biliary cirrhosis and autoimmune hepatitis. (2001) (29)
- CASE REPORT: Trovafloxacin Hepatotoxicity (2001) (29)
- Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B. (2019) (28)
- [786] RESULTS OF AN INTERIM ANALYSIS OF A PHASE 2 STUDY OF TELAPREVIR (VX-950) WITH PEGINTERFERON a-2a AND RIBAVIRIN IN PREVIOUSLY UNTREATED SUBJECTS WITH HEPATITIS C (2007) (28)
- Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. (1999) (28)
- A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C. (2005) (28)
- 2016 LONG-TERM OUTCOMES FOLLOWING COMBINATION TREATMENT WITH BOCEPREVIR PLUS PEG-INTRON/RIBAVIRIN (P/R) IN PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 1 (CHC-G1) (2010) (27)
- Treating Medicaid patients with hepatitis C: clinical and economic impact. (2017) (27)
- Impact of sustained virologic response on risk of type 2 diabetes among hepatitis C patients in the United States (2018) (27)
- Treatment of HBV/HCV coinfection: releasing the enemy within. (2009) (27)
- Resistance-Associated Amino Acid Variants Associated with Boceprevir plus Pegylated Interferon-α2B and Ribavirin in Patients with Chronic Hepatitis C in the Sprint-1 Trial (2013) (26)
- 10 PEGINTERFERON LAMBDA-1A (LAMBDA) COMPARED TO PEGINTERFERON ALFA-2A (ALFA) IN TREATMENT-NAIVE PATIENTS WITH HCV GENOTYPES (G) 2 OR 3: FIRST SVR24 RESULTS FROM EMERGE PHASE IIB (2012) (26)
- Tattoo application is not associated with an increased risk for chronic viral hepatitis (2000) (26)
- 1 ATOMIC: 97% RVR FOR PSI-7977 + PEG/RBV × 12 WEEK REGIMEN IN HCV GT1: AN END TO RESPONSE-GUIDED THERAPY? (2012) (26)
- Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection. (2002) (25)
- Viral eradication is required for sustained improvement of patient‐reported outcomes in patients with hepatitis C (2018) (25)
- Trends in HCV RNA testing among HCV antibody-positive persons in care, 2003-2010. (2014) (24)
- Patient‐Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir (2017) (24)
- Bioelectrical Impedance Analysis for the Evaluation of Hepatic Fibrosis in Patients with Chronic Hepatitis C Infection (2008) (24)
- A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma (2009) (23)
- Pegylated interferon alfa 2b and ribavirin for hepatitis C patients who were nonresponders to previous therapy (2003) (23)
- MAGELLAN-1, Part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic hepatitis C virus genotype 1 or 4 and prior direct-acting antiviral treatment failure (2017) (23)
- Adefovir dipivoxil in chronic hepatitis B: history and current uses (2012) (23)
- Mortality Among Patients With Chronic Hepatitis B Infection: The Chronic Hepatitis Cohort Study (CHeCS) (2018) (23)
- Mortality Among Patients With Chronic Hepatitis B Infection: The Chronic Hepatitis Cohort Study (CHeCS) (2018) (23)
- Epidemiology of Hepatitis C (2018) (22)
- The value of cure associated with treating treatment‐naïve chronic hepatitis C genotype 1: Are the new all‐oral regimens good value to society? (2017) (22)
- Disease Severity Is Associated With Higher Healthcare Utilization in Nonalcoholic Steatohepatitis Medicare Patients. (2019) (22)
- Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders (2009) (22)
- HCV RNA is present in the menstrual blood of women with chronic hepatitis C infection. (1993) (21)
- Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1. (2018) (21)
- O166 ALL-ORAL DUAL THERAPY WITH DACLATASVIR AND ASUNAPREVIR IN PATIENTS WITH HCV GENOTYPE 1B INFECTION: PHASE 3 STUDY RESULTS (2014) (21)
- Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study. (2020) (21)
- Hepatitis B virus infection testing and prevalence among Asian and Pacific Islanders. (2014) (20)
- Chronic Hepatitis C Infection as a Risk Factor for Renal Cell Carcinoma (2015) (20)
- Hepatitis B e Antigen Status and Hepatitis B DNA Levels in Women of Childbearing Age with Chronic Hepatitis B Infection Screening for Clinical Trials (2015) (20)
- Prevalence of Renal Impairment and Associated Conditions Among HCV-Infected Persons in the Chronic Hepatitis Cohort Study (CHeCS) (2016) (20)
- Validity of an automated algorithm using diagnosis and procedure codes to identify decompensated cirrhosis using electronic health records (2017) (20)
- Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings. (2018) (20)
- Trovafloxacin hepatotoxicity (2000) (20)
- Comparison of ICD-9 Codes for Depression and Alcohol Misuse to Survey Instruments Suggests These Codes Should Be Used with Caution (2017) (19)
- High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: integrated efficacy and safety analysis of genotype 1–6 patients without cirrhosis (2017) (19)
- Focal hepatic candidiasis with perihepatic adhesions: laparoscopic and immunohistologic diagnosis. (1990) (18)
- New insights into acute hepatitis C. (2003) (18)
- 744 Sustained virologic response (SVR) to interferon-alpha-2b +/- ribavirin therapy at 6 months reliably predicts long-term clearance of HCV at 5-year follow-up (2006) (18)
- Role of Liver Biopsy in the Era of Direct-Acting Antivirals (2013) (18)
- Use of the methacetin breath test to classify the risk of cirrhotic complications and mortality in patients evaluated/listed for liver transplantation. (2015) (18)
- 45 HBsAg seroconversion in adefovir dipivoxil (ADV) treated chronic hepatitis B (CHB) patients (2004) (18)
- Boceprevir Resistance-Associated Variants (Ravs) Are Observed More Frequently in HCV (GT1)-Infected Patients With Poor Response to Peginterferon Alfa-2B/Ribavirin (2011) (17)
- MAGELLAN-1, Part 2: Glecaprevir and Pibrentasvir for 12 or 16 Weeks in Patients with Chronic HCV Genotype 1 or 4 and Prior Direct-Acting Antiviral Treatment Failure (2017) (17)
- Distribution of disease phase, treatment prescription and severe liver disease among 1598 patients with chronic hepatitis B in the Chronic Hepatitis Cohort Study, 2006–2013 (2016) (17)
- Safety and efficacy of treatment with once-daily ledipasvir/sofosbuvir (90/400 mg) for 12 weeks in genotype 1 hcv-infected patients with severe renal impairment. (2017) (17)
- Alcohol‐related hepatitis admissions increased 50% in the first months of the COVID‐19 pandemic in the USA (2022) (17)
- Locations and Reasons for Initial Testing for Hepatitis C Infection — Chronic Hepatitis Cohort Study, United States, 2006–2010 (2013) (17)
- Experimental evidence against replication or dissemination of hepatitis C virus in mosquitoes (Diptera:Culicidae) using detection by reverse transcriptase polymerase chain reaction. (1996) (16)
- Is Previous Exposure to Hepatitis B a Risk Factor for Pancreatic Cancer or Hepatocellular Carcinoma? (2014) (16)
- Race, Age, and Geography Impact Hepatitis C Genotype Distribution in the United States (2017) (16)
- 9 BOCEPREVIR RESISTANCE-ASSOCIATED VARIANTS (RAVS) ARE OBSERVED MORE FREQUENTLY IN HCV (GT1)-INFECTED PATIENTS WITH POOR RESPONSE TO PEGINTERFERON ALFA-2B/RIBAVIRIN (2011) (16)
- M1908 Tenofovir Disoproxil Fumarate (TDF) for the Treatment of HBeAg-Negative Chronic Hepatitis B: Week 72 TDF Data and Week 24 Adefovir Dipivoxil Switch Data (Study 102) (2008) (15)
- Adjuvant ribavirin and longer direct‐acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure (2019) (15)
- Sustained virological response does not improve long‐term glycaemic control in patients with type 2 diabetes and chronic hepatitis C (2019) (15)
- Safety and efficacy of the fixed-dose combination regimen of MK-3682/grazoprevir/ruzasvir in cirrhotic or non-cirrhotic patients with chronic HCV GT1 infection who previously failed a direct-acting antiviral regimen (C-SURGE) (2017) (14)
- 312 Treatment of chronic hepatitis C with ISIS 14803, an antisense inhibitor of HCV, given for 12 weeks (2003) (14)
- Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American Consortium (2017) (14)
- 865 12 WEEK RESPONSE-GUIDED TREATMENT WITH THE NS5A INHIBITOR, GS-5885, THE NS3 PROTEASE INHIBITOR, GS-9451, PLUS PEGYLATED INTERFERON/RIBAVIRIN IN TREATMENT NAÏVE GENOTYPE 1 HEPATITIS C INFECTED PATIENTS (2013) (14)
- Frequencies of Resistance-Associated Amino Acid Variants Following Combination Treatment with Boceprevir Plus PEGINTRON (PegInterferon Alfa-2b)/Ribavir in in Patients With Chronic Hepatitis C (CHC), Genotype 1 (G1) (2010) (14)
- Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C (2016) (14)
- Adherence to Assigned Dosing Regimen and Sustained Virologic Response Among Hepatitis C Genotype 1 Treatment-NaïVE and PEG/Ribavirin Treatment-Failures Treated With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin (2011) (13)
- Testing and Clinical Management of Health Care Personnel Potentially Exposed to Hepatitis C Virus — CDC Guidance, United States, 2020 (2020) (13)
- Successful treatment of hepatitis B-associated vasculitis with lamivudine. (2001) (13)
- Mitochondrial antigens as targets of cellular and humoral auto-immunity in primary biliary cirrhosis (2005) (13)
- Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases (2020) (13)
- Changing trends in complications of chronic hepatitis C (2018) (13)
- Management of Acute Hepatotoxicity Including Medical Agents and Liver Support Systems. (2017) (12)
- Major hemorrhage after percutaneous liver biopsy in patients with AIDS. (1991) (12)
- Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non‐adherence (2020) (12)
- Epidemiology of hepatitis C virus infection in a suburban Detroit community. (1991) (12)
- Ursodeoxycholic Acid Treatment Preferentially Improves Overall Survival Among African Americans With Primary Biliary Cholangitis. (2020) (12)
- Budd-Chiari syndrome complicating pre-eclampsia: diagnosis by magnetic resonance imaging. (1991) (12)
- Mental and physical health status among chronic hepatitis B patients (2020) (11)
- Clinical and Patient Reported Outcomes from Patients with Non-alcoholic Fatty Liver Disease Across the World: Data from the Global NASH/NAFLD Registry. (2021) (11)
- 428 ADHERENCE TO ASSIGNED DOSING REGIMEN AND SUSTAINED VIROLOGIC RESPONSE AMONG HEPATITIS C GENOTYPE 1 TREATMENT-NAIVE AND PEG/RIBAVIRIN TREATMENT-FAILURES TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN (2011) (11)
- 6 ALL ORAL THERAPY WITH SOFOSBUVIR + RIBAVIRIN FOR 12 OR 16 WEEKS IN TREATMENT EXPERIENCED GT2/3 HCV-INFECTED PATIENTS: RESULTS OF THE PHASE 3 FUSION TRIAL (2013) (11)
- 5 PHASE 3 RANDOMIZED CONTROLLED TRIAL OF ALL-ORAL TREATMENT WITH SOFOSBUVIR + RIBAVIRIN FOR 12 WEEKS COMPARED TO 24 WEEKS OF PEG + RIBAVIRIN IN TREATMENT-NAÏVE GT2/3 HCV-INFECTED PATIENTS (FISSION) (2013) (11)
- LBP-13-Effect of treatment of hepatitis B patients with tenofovir disoproxil or entecavir on risk of hepatocellular cancer death in a U.S. Cohort (2019) (11)
- Risk Factors for Hepatitis C Infection Among Vietnam Era Veterans Versus Nonveterans: Results from the Chronic Hepatitis Cohort Study (CHeCS) (2014) (11)
- Current pharmacotherapy for hepatitis B infection (2001) (11)
- A Phase I, Randomized, Placebo-Controlled, 3-Day, Ascending-Dose Study of Gs-9451, An Ns3/4A Protease Inhibitor, in Genotype 1 Hepatitis C Patients (2013) (10)
- Hepatitis A and B immunity and vaccination in chronic hepatitis B and C patients in a large United States cohort. (2015) (10)
- Gastrointestinal hemorrhage secondary to crack cocaine. (1995) (10)
- Comparative histologic features of liver biopsy specimens from patients coinfected with hepatitis G and C viruses with chronic hepatitis C virus alone: an age-, sex-, disease duration-, and transmission-matched controlled study of chronic hepatitis. (1997) (10)
- Hepatitis C Virus Infection Care Pathway-A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group. (2017) (10)
- 804 SUSTAINED VIROLOGIC RESPONSE AFTER PEGINTERFERON ALFA-2B AND RIBAVIRIN TREATMENT PREDICTS LONG-TERM CLEARANCE OF HCV AT 5-YEAR FOLLOW-UP (2008) (10)
- Psychosocial Obstacles to Hepatitis C Treatment Initiation Among Patients in Care: A Hitch in the Cascade of Cure (2020) (10)
- No Impact of Rass on the High Efficacy of SOF/VEL/VOX for 12 Weeks in Daa-Experienced Patients: An Integrated Resistance Analysis of the Polaris-1 and Polaris-4 Studies (2017) (9)
- [649] CPG 10101 (ACTILON) IN COMBINATION WITH PEGYLATED INTERFERON AND/OR RIBAVIRIN IN CHRONIC HCV GENOTYPE 1 INFECTED PATIENTS WITH PRIOR RELAPSED RESPONSE: WEEK 48 DATA (2007) (9)
- Novel Therapies in Hepatic Encephalopathy. (2020) (9)
- Low Uptake of Direct-acting Antiviral Therapy Among Hepatitis C Patients With Advanced Liver Disease and Access to Care, 2014-2017 (2020) (9)
- Long‐term progression of viral load and serum markers of fibrosis among treated and untreated patients with chronic hepatitis B (2017) (9)
- Occult Viral Hepatitis and Noncirrhotic Hepatocellular Carcinoma (2005) (9)
- Histologic spectrum of cryptogenic chronic liver disease and comparison with chronic autoimmune and chronic type C hepatitis. (1995) (9)
- Baricitinib and primary biliary cholangitis (2021) (9)
- S1001 Clearance of HCV At 5 Year Follow-Up for Peginterferon Alfa-2b ± Ribavirin Is Predicted By Sustained Virologic Response At 24 Weeks Post Treatment (2008) (8)
- Autoantibodies to specific enzymes: a review. (1996) (8)
- Comparative Effectiveness Research of Chronic Hepatitis B and C Cohort Study (CHeCS): Improving Data Collection and Cohort Identification (2014) (8)
- Review article: HCV ? STAT-C era of therapy (2010) (8)
- 223 Prove1: Results from a Phase 2 Study of Telaprevir with Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Subjects with Hepatitis C (2008) (8)
- A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. (2022) (8)
- High SVR Rates with Eight and Twelve Weeks of Pangenotypic Glecaprevir/Pibrentasvir: Integrated Efficacy Analysis of Genotype 1-6 Patients Without Cirrhosis (2017) (8)
- All-oral Dual Therapy with Daclatasvir and Asunaprevir in Patients with HCV Genotype 1B Infection (2014) (7)
- Acute Hepatitis B in an Urban Tertiary Care Hospital in the United States: A Cohort Evaluation (2013) (7)
- Prevalence of anti-HCV in cryptogenic cirrhosis in a suburban Detroit community. (1992) (7)
- A flow cytometric method to detect anti-pyruvate dehydrogenase antibody in primary biliary cirrhosis. (1992) (7)
- 964 THE FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) INCREASES PLASMA FGF-19 CONCENTRATIONS AND DECREASES BILE ACID SYNTHESIS IN PRIMARY BILIARY CIRRHOSIS (PBC) (2012) (7)
- HLA haplotypes in primary sclerosing cholangitis patients of admixed and non‐European ancestry (2017) (7)
- Anabolic steroid-induced cholestasis: choleretic response to corticosteroids. (1988) (7)
- Treatment of viral hepatitis - 2001 (2001) (7)
- 111 Final results of a multi-center phase 1b, randomized, placebo-controlled, doseescalation trial of CPG 10101 in patients with chronic hepatitis C virus (2006) (7)
- IMO-2125, A TLR9 AGONIST, INDUCES IMMUNE RESPONSES WHICH CORRELATE WITH REDUCTIONS IN VIRAL LOAD IN NULL RESPONDER HCV PATIENTS (2010) (7)
- O001 : C-salvage: grazoprevir (GZR; MK-5172), elbasvir (EBR; MK-8742) and ribavirin (RBV) for chronic hcv-genotype 1 (GT1) infection after failure of direct-acting antiviral (DAA) therapy (2015) (7)
- Renal insufficiency after liver transplantation in the MELD era compared to the pre‐MELD era (2009) (6)
- Review article: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data (2022) (6)
- Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study (2020) (6)
- BUDD-CHIARI AND INFARCT IN PREGNANCY (1999) (6)
- Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts (2021) (6)
- Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml) (2015) (6)
- Hepatocellular Carcinoma Surveillance in a Cohort of Chronic Hepatitis C Virus-Infected Patients with Cirrhosis (2019) (6)
- Hepatitis C Virus: A Critical Appraisal of New Approaches to Therapy (2012) (6)
- Health Care Use and Costs Among Patients With Nonalcoholic Steatohepatitis With Advanced Fibrosis Using the Fibrosis‐4 Score (2020) (6)
- 628 RANDOMIZED TRIAL COMPARING SYSTEMIC AND LOCAL REACTIONS TO CONTROLLED-RELEASE INTERFERON ALPHA2B AND PEGYLATED-INTERFERON ALPHA2B IN HEPATITIS C PATIENTS WHO FAILED PRIOR TREATMENT (2009) (6)
- Hepatitis C screening: summary of recommendations from the clinical decision tool. (2013) (5)
- 764 Sofosbuvir/Ledipasvir With and Without Ribavirin for 8 Weeks Compared to Sofosbuvir/Ledipasvir for 12 Weeks in Treatment-Naive Non-Cirrhotic Genotype-1 HCV-Infected Patients: The Phase 3 Ion-3 Study (2014) (5)
- Cost-effectiveness of pan-genotypic direct-acting antiviral regimens for treatment of chronic Hepatitis C in the United States (2020) (5)
- 818 HCV-TARGET: A LONGITUDINAL, OBSERVATIONAL STUDY OF NORTH AMERICAN PATIENTS WITH CHRONIC HEPATITIS C (HCV) TREATED WITH BOCEPREVIR OR TELAPREVIR (2013) (5)
- Risk of hepatocellular carcinoma in treatment‐naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States (2022) (5)
- 836 Sustained Virologic Response (SVR) in Prior Peginterferon/Ribavirin (PR) Treatment Failures After Retreatment With Boceprevir (BOC) + PR: the Provide Study Interim Results (2012) (5)
- Hepatitis C Virus Detection and Treatment in Rural Communities. (2018) (5)
- Scintigraphic and culdoscopic diagnosis of bile peritonitis complicating liver biopsy. (1989) (5)
- Hepatitis B Virus Infection and Hepatitis C Virus Treatment in a Large Cohort of Hepatitis C-Infected Patients in the United States. (2018) (5)
- THU-405-Complications of chronic hepatitis B: Prevalence and disparities in a US health system cohort 2006-2016 (2019) (5)
- Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6 (2019) (5)
- Predictors of consent to pharmacogenomics testing in the IDEAL study (2011) (5)
- Safety and Pharmacodynamics of Oral TLR-7 agonist GS-9620 in patients with Chronic Hepatitis B (2013) (5)
- Normal alkaline phosphatase levels are dependent on race/ethnicity: National Health and Nutrition Examination Survey data (2020) (5)
- Frequency of and Factors Associated with Receipt of Liver-Related Specialty Care Among Patients with Hepatitis C in the Chronic Hepatitis Cohort Study (2016) (5)
- Case report: Acute type a hepatitis presenting with hypotension, bradycardia, and sinus arrest (1989) (5)
- P1171 INTEGRATED SAFETY ANALYSIS OF SOFOSBUVIR-BASED HCV TREATMENT REGIMENS FROM PHASE 3 STUDIES (2014) (4)
- 745 Efficacy and safety of eltrombopag, an oral platelet growth factor, in subjects with HCV associated thrombocytopenia: Preliminary results from a phase II dose-ranging study (2006) (4)
- Impact of sustained virological response on incidence of type 2 diabetes in hepatitis c patients. (2017) (4)
- Treatment efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12- and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study (2018) (4)
- Availability of PEth testing is associated with reduced eligibility for liver transplant among patients with alcohol‐related liver disease (2022) (4)
- P374 LONG-TERM TREATMENT OF PRIMARY BILIARY CIRRHOSIS WITH THE FXR AGONIST OBETICHOLIC ACID SHOWS DURABLE EFFICACY (2014) (4)
- Advancing Age and Comorbidities in Chronic Hepatitis B Patients: Results of 10-Year Longitudinal Analysis of a Diverse Population-Based Cohort of 44,026 Chronic Hepatitis B Patients in the United States (2017) (4)
- Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection (2019) (4)
- Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks Compared to Sofosbuvir with Ribavirin for 24 Weeks in Genotype 3 HCV Infected Patients: The Randomized Controlled Phase 3 ASTRAL-3 Study (2015) (4)
- Higher and Rising Prevalence and Incidence of Renal Impairment and Chronic Kidney Disease in Chronic Hepatitis B Patients Compared to Matched Non-Chronic Hepatitis B Controls in the United States: Results of a Real-World Analysis (2017) (4)
- Hepatic Manifestations of Systemic Disorders (2011) (4)
- HCV Council – critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape (2015) (4)
- P0889 : Effect of baseline factors on response to the fixed-dose combination of daclatasvir (DCV), asunaprevir (ASV) and beclabuvir (BCV) in non-cirrhotic patients with HCV genotype 1 infection (2015) (4)
- 952 LONG-TERM (LT) THERAPY OF A FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) MAINTAINS BIOCHEMICAL RESPONSE IN PRIMARY BILIARY CIRRHOSIS (PBC) (2012) (4)
- Efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis: 52-week analysis of an ongoing international, randomized, dose ranging phase 2 study. (2018) (4)
- 1181 PHARMACOGENOMIC ANALYSIS REVEALS IMPROVED VIROLOGIC RESPONSE IN ALL IL-28B GENOTYPES IN NAIVE GENOTYPE 1 CHRONIC HCV PATIENTS TREATED WITH GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN (2010) (3)
- IDDF2018-ABS-0113 The safety and tolerability of sof/vel/vox for 8 or 12 weeks in >1,000 patients treated in the polaris-1, polaris-2, polaris-3, and polaris-4 studies: an integrated analysis (2017) (3)
- INCREASING INCIDENCE OF HEPATOCELLULAR CARCINOMA IN THE UNITED STATES: TRENDS IN A CLINICAL HEPATOLOGY PRACTICE (2004) (3)
- Short Duration Treatment with Sofosbuvir/Velpatasvir plus GS-9857 in Treatment-Naive Genotype 1-6 HCV-Infected Patients with or without Cirrhosis (2016) (3)
- Hepatitis C Virus-Associated Aortitis Caused by Type I Cryoglobulins (2017) (3)
- Jaundice and cholestasis. Some common and uncommon causes. (1991) (3)
- Antiviral therapy for chronic hepatitis B and C (2000) (3)
- The safety of daclatasvir for the treatment of hepatitis C (2015) (3)
- A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Trial of Merimepodib (VX-497) and Interferon-α in Previously Untreated Patients with Chronic Hepatitis C (2005) (3)
- Immunoglobulin M antibody to hepatitis B core antigen and fulminant hepatitis B. (1985) (3)
- Efficacy and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir with ribavirin in adults with genotype 1 or genotype 4 chronic hepatitis C virus infection and child-pugh B decompensated cirrhosis (2017) (3)
- Increasing healthcare resource utilization (HCRU) and costs associated with advanced liver disease-a multivariate analyses of real-world medicare nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/ NASH) patients. (2018) (3)
- 647 TREATMENT OF HEPATITIS C WITH THE IMMUNE- STIMULATING DIPEPTIDE SCV-07 (2009) (3)
- Hepatitis C: Does Successful Treatment Alter the Natural History and Quality of Life? (2020) (3)
- Does Hepatitis C eradication lead to improved glucose metabolism, renal and cardiovascular outcomes in diabetic patients? (2017) (3)
- Prevalence of Osteoporosis and Bone Fracture was 2-Fold Higher in Chronic Hepatitis B Compared to Non-Chronic Hepatitis B Patients and Continued to Increase in the Last Decade: Results of a United States Population-Based Cohort Study (2017) (3)
- Trends in Diagnosed Chronic Hepatitis B in a US Health System Population, 2006–2015 (2019) (3)
- Utility of IL-28B Polymorphisms in the Era of Direct-Acting Antiviral Therapy. (2011) (2)
- Management of Chronic Viral Hepatitis (2001) (2)
- Immunological responses in patients who have spontaneously eradicated hepatitis C virus infection. (2000) (2)
- [632] IMPACT OF TARIBAVIRIN EXPOSURE ON EFFICACY, ANEMIA RATES, AND Gl SIDE EFFECTS WHEN USED WITH PEGYLATED INTERFERON ALFA-2b FOR THE TREATMENT OF CHRONIC HEPATITIS C (2007) (2)
- Boceprevir Plus Peginterferon &agr;-2b/Ribavirin in Chronic Hepatitis C Genotype 1: Impact of Baseline Viral Load on Sustained Virologic Response (2013) (2)
- IDDF2018-ABS-0114 SOF/VEL/VOX results in high SVR12 rates when administered for 12 weeks in DAA-experienced patients or for 8 weeks in daa-naive patients: an integrated analysis of the polaris-1, polaris-2, polaris-3 and polaris-4 studies (2017) (2)
- Polycystic Liver Disease. (2015) (2)
- Management of Direct‐Acting Antiviral Failures (2020) (2)
- Sofosbuvir + Ribavirin With or Without Peginterferon Is Well-Tolerated and Associated with High SVR Rates: Integrated Results from 4 Phase 3 Trials in HCV Genotype 1-6: 412 (2013) (2)
- Cost-effectiveness analysis of first-line administration of tenofovir alafenamide (TAF), a novel nucleotide reverse transcrip-tase inhibitor (NRTI), for the management of chronic hepatitis b (CHB) in the united states (us). (2017) (2)
- 3 Times Higher Healthcare Cost in Chronic Hepatitis B Patients Compared to Non-Chronic Hepatitis B Controls Especially Those with Decompensated Liver Disease: United States Real World Healthcare Utilization and Cost Analysis (2017) (2)
- 650 Integrated Safety Analysis of Sofosbuvir-Based HCV Treatment Regimens From Phase 3 Studies (2014) (2)
- A Case of Hemophagocytic Lymphohistiocytosis Secondary to Disseminated Histoplasmosis (2020) (2)
- A Point System to Forecast Hepatocellular Carcinoma Risk Before and After Treatment Among Persons with Chronic Hepatitis C (2017) (2)
- Serum bilirubin within normal range is associated with an increasing risk of mortality in patients with primary biliary cholangitis regardless of ursodeoxycholic acid treatment. Hepatology 2018; 68:31A-32A. (2018) (2)
- Sex Differences in Extrahepatic Outcomes After Antiviral Treatment for Hepatitis C. (2020) (2)
- Preliminary results of the NYNEST interferon-Ribavirin re-treatment trial in non-responders and relapsers with chronic hepatitis C (1998) (2)
- Laparoscopic diagnosis of subcapsular hepatic hemorrhage in pre-eclamptic liver disease. (1992) (2)
- C-BREEZE 1: Efficacy and safety of ruzasvir 60 mg plus uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis c virus (HCV) genotype (GT)1, 2, 3, 4, or 6 infection. (2017) (2)
- 1116 EXPOSURE-RESPONSE RELATIONSHIPS IN TELAPREVIR COMBINATION THERAPY IN TREATMENT-NAIVE GENOTYPE 1 CHRONIC HCV PATIENTS (2012) (2)
- Sa1046 Efficacy of 5 Years of Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B Patients With High Viral Load (HBV DNA=9 Log10 Copies/Ml) (2012) (2)
- Care of the cirrhotic patient. (2012) (2)
- Epidemiologic trends and treatment survival benefits in a US cohort of patients with primary biliary cholangitis (PBC). (2017) (2)
- Corrigendum: Genome-Wide Analysis of DNA Methylation, Copy Number Variation, and Gene Expression in Monozygotic Twins Discordant for Primary Biliary Cirrhosis (2014) (2)
- 896 - Utilization and Expenditures for Non-Alcoholic Steatohepatitis/Non-Alcoholic Fatty Liver Disease Patients with Advance Fibrosis and Compensated Cirrhosis: Results of a Real-World Analysis Among us Patients (2018) (2)
- 1202 Comparison of low dose with standard dose PEG-interferon alfa-2B plus rivavirin for initial treatment of chronic hepatitis C (2003) (2)
- Rising and higher healthcare resource utilization (HCRU) and costs of nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) patients with advanced liver disease of increasing severity-results of a US real-world analysis. (2018) (2)
- 748 United States Multicenter Study of Ultrasonic TRANSIENT ELASTOGRAPHY (FibroScan) for the Diagnosis of Cirrhosis and Fibrosis in Patients with Hepatitis B and C (2009) (2)
- 835 Exposure-Response Relationships in Telaprevir Combination Therapy in Treatment-NaïVE Genotype 1 Chronic HCV Patients (2012) (2)
- Viral hepatitis: Practical evaluation and treatment. By Teddy F. Bader. 248 pp. Seattle: Hogrefe & Huber, 1994. $49 (1995) (1)
- The Impact of Patient Preferences on Pancreatic Cyst Management: 229 (2013) (1)
- African Americans Demonstrate Significantly Lower Serum Alanine Aminotransferase Compared to Non-African Americans (2020) (1)
- Novel protease and polymerase inhibiting agents to treat chronic hepatitis C infection (2008) (1)
- Tu1497 – Efficacy and Safety of Sofosbuvir/Velpatasvir for the Treatment of Patients with Chronic Hepatitis C Genotype 1-6 Infection: Integrated Analysis of Eight Phase 3 Clinical Trials (2019) (1)
- "Love Boat" hepatitis. (1985) (1)
- Choledochocele: its clinical spectrum. (1985) (1)
- Late diagnosis of hepatitis C virus infection, 2014-2016: continuing missed intervention opportunities. (2019) (1)
- M1907 Efficacy of Entecavir in Nucleoside-NaïVe Patients with Mildly Elevated ALT (2008) (1)
- 1001 Relationship between hepatic iron content and histological response in chronic hepatitis C (2003) (1)
- 329 THE IMPACT OF FATIGUE ON PATIENT-REPORTED OUTCOMES (PRO) IN PATIENTS WITH CHRONIC LIVER DISEASE (CLD): DATA FROM THE GLOBAL LIVER REGISTRY (GLR) (2020) (1)
- Dynamic Risk Prediction of Response to Ursodeoxycholic Acid Among Patients with Primary Biliary Cholangitis in the USA (2021) (1)
- 408 WATS Brushings Are More Sensitive for Detecting Intestinal Metaplasia in Barrett’s Esophagus Than Concurrent Forceps Biopsies: Results From a National Registry (2019) (1)
- 468 UNIQUE PATTERN OF VIROLOGIC RESPONSE IN PATIENTS WITH GENOTYPE-1 HCV: A PHASE II STUDY OF CTS-1027 IN COMBINATION WITH PEGINTERFERON/RIBAVIRIN (SOC) IN NULL RESPONDERS (2011) (1)
- The Consequences of Cirrhosis in America (2015) (1)
- 291 - Long-Term Follow-Up of Patients with Chronic HCV and F2 or F3 Fibrosis after Achieving SVR with Daa-Based Therapy: Results from the Gilead SVR Registry (2018) (1)
- Higher Resource Utilization and Healthcare Costs in Treated Chronic Hepatitis B Patients with Chronic Kidney Disease (2017) (1)
- Impact of elbasvir/grazoprevir (EBR/GZR) on health-related quality of life (HRQOL) and fatigue in patients with chronic hepatitis C virus (HCV) infection and inherited blood disorders (IBLD): data from the C-EDGE IBLD study (2017) (1)
- 410 24-WEEK TREATMENT WITH CTS-1027 IN COMBINATION WITH RIBAVIRIN REDUCES HCV-RNA IN TREATMENT NAIVE GENOTYPE-1 PATIENTS (2011) (1)
- Successful treatment of multi-drug resistant hepatis C after >12 months of continuous therapy with direct-acting antivirals. (2022) (1)
- Occlusion Rate and Complications of Plastic Biliary Stents in Patients Undergoing Neoadjuvant Chemoradiotherapy for Pancreatic Cancer Associated with Biliary Obstruction: 237 (2008) (1)
- Real world effectiveness of 8 vs 12 weeks of ledipasvir/sofosbuvir (LDV/SOF) in blacks with HCV: A comparative analysis of clinical trials with real world cohorts. (2017) (1)
- Patient-reported outcomes in chronic hepatitis C: The impact of placebo, active treatment, and sustained viral eradication (2018) (1)
- PS-122-Seladelpar for the treatment of primary biliary cholangitis: Experience with 26 cirrhotic patients (2019) (1)
- High efficacy is accompanied with substantial gains in patient reported outcomes in cirrhotic patients with chronic hepatitis C treated with sofosbuvir (SOF), velpatasvir with or without voxilaprevir (VOX): data from POLARIS 1, 2, 3 and 4 (2017) (1)
- Health outcomes associated with sofosbuvir- based single-tablet regimens for initial and re-treatment of chronic hepatitis c in the US. (2017) (1)
- The clinical and patient reported outcomes (PROs) profile of patients with non-alcoholic fatty liver disease (NAFLD) from real-world practices varies across the world (2020) (1)
- Long-term follow up of patients with chronic HCV and F2 or F3 fibrosis after achieving SVR with DAA-based therapy: results from the Gilead SVR registry (2018) (1)
- Update on Polycystic Liver Disease. (2020) (1)
- The persistence of underreporting of hepatitis C as an underlying or contributing cause of death, 2011-2017. (2021) (1)
- 1254-P: Increased Health-Care Resource Utilization (HRU) and Costs among Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) Patients with Advanced Fibrosis (AF) having Diabetes Mellitus (DM) (2019) (1)
- The burden of acute non-fulminant drug-induced liver disease in the United States (2003) (1)
- 294 - Retreatment of Patients who Failed Glecaprevir/Pibrentasvir Treatment for Hepatitis C Virus Infection (2018) (1)
- Use of Billing and Procedure Codes to Predict Stage of Liver Disease in Patients with Chronic Viral Hepatitis: 496 (2013) (1)
- P1220 MODELING PREDICTS CLINICALLY MEANINGFUL SVR RATES IN GENOTYPE 1 TREATMENT-EXPERIENCED PATIENTS BASED ON RESULTS IN GENOTYPE 1 TREATMENT-NAIVE PATIENTS TREATED WITH SOFOSBUVIR + PEGINTERFERON + RIBAVIRIN FOR 12 WEEKS (2014) (1)
- Post-transplant course of hepatitis C after living donor liver transplantation in association with polymorphisms near IFNL3. (2015) (1)
- P0770 : Effect of hepatitis C antiviral therapy on all-cause mortality and development of cancer in the chronic hepatitis cohort study (CHeCS) (2015) (1)
- P1034 ESTIMATED PREVALENCE OF HCV CIRRHOSIS IN THE CHRONIC HEPATITIS COHORT STUDY (CHECS) (2014) (1)
- Sofosbuvir/Velpatasvir (SOF/VEL) with or without Voxilaprevir (VOX) is Associated with Excellent Efficacy and Significant Improvements of Patient-Reported Outcomes (PROS) During Treatment and After Achieving Sustained Virologic Response (SVR) (2017) (1)
- Fibrosis-4 score (FIB-4) provides consistent assessment of healthcare costs and healthcare resource utilization (HCRU) among nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients with advanced fibrosis. (2018) (1)
- Resection of metachronous hepatocellular carcinomas. (1986) (1)
- The Impact of Prior Biliary Stenting on the Accuracy and Complication Rate of EUS-FNA for Diagnosing Pancreatic Adenocarcinoma: 158 (2009) (1)
- 418 UTILITY OF HISTORICAL DATA COMPARED TO LEAD-IN RESPONSE IN PREDICTING SUSTAINED VIROLOGIC RESPONSE IN NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR+PEGINTERFERON ALFA-2B/RIBAVIRIN (P/R) (2011) (1)
- Trends in Cirrhosis and Mortality by Age, Sex, Race, and Antiviral Treatment Status Among US Chronic Hepatitis B Patients (2006-2016) (2021) (1)
- Rising Healthcare Utilization and Cost of Chronic Hepatitis B: Real-World Analysis of 44,026 Chronic Hepatitis B Patients and 121,568 Matched Non-Chronic Hepatitis B Controls in the United States (2017) (1)
- IDDF2019-ABS-0134 Sofosbuvir/velpatasvir is effective and safe in patients with concomitant proton pump inhibitor use in clinical studies (2019) (1)
- Love Boat" hepatitis. (1985) (1)
- Virologic Response Rates to Fixed-Dose Combination Ledipasvir/Sofosbuvir for 8 or 12 Weeks With Baseline Viral Load: 2061 (2015) (0)
- Liver diseases in the elderly. (1991) (0)
- IDDF2018-ABS-0111 Safety and efficacy of treatment with once-daily LEDIPASVIR/SOFOSBUVIR (90/400 MG) for 12 weeks in genotype 1 hcv-infected patients with severe renal impairment (2018) (0)
- Severe impairment of patient‐reported outcomes in patients with chronic hepatitis C virus infection seen in real‐world practices across the world: Data from the global liver registry (2022) (0)
- High SVR Rates with 8 and 12 Weeks of Pangenotypic GlecapreviriPibrentasvir: PH2Integrated Efficacy and Safety Analysis of Genotype 1-6 Patients without Cirrhosis (2017) (0)
- SIRS is the Optimal Simple Predictor of Severity in Acute Pancreatitis: Presidential Poster: 226 (2013) (0)
- Does the Type of Pancreatic Malignancy Influence the Number of Fine Needle Aspiration Attempts? A Comparison Between Pancreatic Adenocarcinoma and Islet Cell Neoplasms: 230 (2012) (0)
- A Rare Cause for Persistent Esophageal Leak after Esophagectomy: Gastric Perforation from a Chest Tube: 589 (2012) (0)
- S1208 Prevalence of Hepatitis B Virus (HBV) and Latent Tuberculosis Co-Infection and Risk of Drug-Induced Liver Injury Across Two Large HBV Cohorts in the United States (2022) (0)
- 62 CONSISTENT DNA METHYLATION DIFFERENCES IN 46 GENOME-WIDE LOCI IN MONOZYGOTIC TWINS DISCORDANT FOR PRIMARY BILIARY CIRRHOSIS (2010) (0)
- 812 A Cost-Effectiveness Analysis of LDV/SOF+RBV for 12 Weeks vs. LDV/SOF 24 Weeks vs. SOF+SMV 24 Weeks in CHC Gt1 TE Cirrhotic Patients (2015) (0)
- Long-Term Fibrosis and Viral Level Progression among Treated and Untreated Patients with Chronic Hepatitis B (2016) (0)
- Reevaluation of the Upper Limit of Normal for Outpatient Alanine Aminotransferase (ALT) Levels at a Large United States Urban Medical Center: 436 (2014) (0)
- Presence of advanced liver disease concurrent with initial diagnosis of Hepatitis C virus (HCV) infection among patients in the chronic hepatitis cohort study (CHECS) 2014-16: Missed opportunities for intervention. (2018) (0)
- Second Generation Protease Inhibitors and Nucleotide Inhibitors (2012) (0)
- Sacrificing Affordability in the Name of Proving Efficacy: The Case of Pancreatic Enzyme Replacement Therapy: 224 (2013) (0)
- Clinical and patient‐reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry™ (2023) (0)
- Tu2049 Projection of Health Outcomes Comparing LDV/SOF vs. SOF+SMV - An Analysis Based on Clinical Trial vs. Real-World Data (2015) (0)
- Health and economic outcomes of sofosbuvir therapy as predicted by a Markov model in the HCV/HIV co-infected cohort (2014) (0)
- Non-Invasive Predictors of Advanced Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: 266 (2005) (0)
- Extended Re-Treatment for Chronic Hepatitis C Genotype 1 Patients Who Previously Relapsed Following 48 Week PEG/Ribavirin Therapy: 430 (2006) (0)
- Recurrent Appendicitis; Six Operations with Six Recoveries; Treatment for Acute Attack in Five Cases (1893) (0)
- Sa313 CLINICAL PRESENTATION AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC VIRAL HEPATITIS: DATA FROM THE GLOBAL LIVER REGISTRY™ (2021) (0)
- HIV co-infection is associated with increased liver complications and reduced mental health among patients with chronic hepatitis B (2018) (0)
- Lean non-alcoholic fatty liver disease patients from the global NASH registry (2022) (0)
- Diagnosis and management of chronic hepatitis C virus infection (2001) (0)
- 765 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOSE RESPONSE (RPCDBDR) TRIAL OF CTS-1027, AN INHIBITOR OF MATRIX METALLOPROTEASES (MMPS) IN PATIENTS WITH HCV WHO HAD FAILED PRIOR THERAPIES (2010) (0)
- Staufferʼs Syndrome: Renal Cell Carcinoma Presenting as Abnormal LFTs: 735 (2015) (0)
- PE-056 : The Safety and Tolerability of SOF/VEL/VOX for 8/12 Weeks in >1,000 Patients Treated in the POLARIS Studies: An Integrated Analysis (2017) (0)
- Response to: ‘No impact of Covid‐19 pandemic on decompensation of alcoholic liver disease: Results from a single Center in Milan’ (2022) (0)
- CB3-02: Demographic Differences Between US-born and Foreign-born Asia Pacific Islanders Among the Hepatitis B Patients of Kaiser Permanente, Hawai’i (2012) (0)
- O.105 Early clinical results with CPG 10101, a new investigational antiviral TRL9 agonist being developed for treatment of subjects chronically infected with hepatitis C virus (2006) (0)
- Reporting of Findings on EUS Examinations for Chronic Pancreatitis: Toward Establishing Benchmarks for EUS Quality: 231 (2012) (0)
- Su1348: EFFICACY, SAFETY, AND TOLERABILITY OF SELADELPAR IN PATIENTS WITH COMPENSATED LIVER CIRRHOSIS DUE TO PRIMARY BILIARY CHOLANGITIS (PBC); A POOLED ANALYSIS OF PHASE 2 AND PHASE 3 STUDIES (2022) (0)
- Endoscopic Ultrasound-Guided Gastro-gastrostomy for Surveillance of Gastric MALT Lymphoma in a Roux-en-Y Gastric Bypass Patient: 2047 (2017) (0)
- P661 APRI AND FIB-4 VS HISTOLOGY IN CHB PATIENTS IN TENOFOVIR DISOPROXIL FUMARATE (TDF) CLINICAL TRIALS (2014) (0)
- Air Embolism: A Rare Complication of ERCP: 803 (2012) (0)
- Minocycline hepatitis: clinical and histopathologic features and comparison with autoimmune hepatitis (2000) (0)
- Impact of hepatitis C treatment status on risk of Parkinson's disease and secondary parkinsonism in the era of direct-acting antivirals. (2023) (0)
- P0778 : The effect of HCV antiviral therapy on fibrosis progression (2015) (0)
- PARAESOPHAGEAL VARICES MIMICKING A MEDIASTINAL MASS MADE APPARENT BY ENDOSCOPIC ULTRASOUND: 574 (2004) (0)
- Body Mass Index Does Not Impact the Efficacy of Avatrombopag in Increasing Platelet Counts and Reducing Platelet Transfusions or Rescue Procedures for Bleeding in Cirrhotic Patients with Thrombocytopenia: Presidential Poster Award (2018) (0)
- MST Criteria to Diagnose Chronic Pancreatitis Are Inaccurate Among Expert Endosonographers: 235 (2014) (0)
- HEPATITIS C AS A RISK FACTOR FOR RENAL CELL CARCINOMA (2009) (0)
- Anabolic Steroid Induced Cholestasis Secondary to a Dietary Supplement: 942 (2006) (0)
- Comparative analysis of direct-acting antiviral regimens across Hepatitis C genotypes and clinical characteristics among patients under routine clinical care in the US. (2018) (0)
- S1010 Effect of Renal Function On Dose Reduction and Sustained Viral Response in Patients with Hepatitis C Treated with Pegylated Interferon and Ribavirin (2008) (0)
- Mo1919 Chronic Aminotransferase Elevation Confounds Transient Elastography in HCV Patients With Early Stage Fibrosis (2012) (0)
- Mo1168 Reduction in Clinical and Economic Burden by Treating All Medicaid Patients With Chronic Hepatitis C (CHC): A Decision-Analytic Model (2016) (0)
- HEREDITARY HEMORRHAGIC TELANGIECTASIA AND SYMPTOMATIC LIVER DISEASE: 561 (2004) (0)
- FRI-023-Inadequate response to UDCA among PBC patients under routine care in the US: Rising serum bilirubin even in the normal range is a risk factor and subsequent clinical follow-up differs based on treatment response (2019) (0)
- P0729 : Renal disease prevalence and association with hepatic fibrosis measured by FIB4 score among US patients with chronic hepatitis C virus (HCV) infection in the chronic hepatitis cohort study (CHeCS) (2015) (0)
- P1052 DETERMINANTS OF VARIABILITY IN ISG15 GENE EXPRESSION IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) INFECTION DURING TREATMENT WITH ORAL TLR7 AGONIST GS-9620 (2014) (0)
- Survival Effect of Palliative Cryoablation Therapy in Patients With Locally Advanced Esophageal Cancer: 2017 Presidential Poster Award: 318 (2017) (0)
- Rare Case of Acute Liver Failure Caused by Diffuse Liver Metastases in a Patient With Non-Muscle Invasive Transitional Cell Carcinoma of the Bladder: 1323 (2014) (0)
- Abnormal Duodenal [HCO3-] Following Secretin Stimulation Develops Sooner than Endocrine Insufficiency in Minimal Change Chronic Pancreatitis: 189 (2010) (0)
- High Burden of GI Disease and Unmet Need in Rwanda: Findings From Rwanda Endoscopy Week (2018) (0)
- P748 CHRONIC HEPATITIS C INFECTION AS A RISK FACTOR FOR RENAL CELL CARCINOMA (2014) (0)
- PIN26 COST-MINIMIZATION ANALYSIS OF PAN-GENOTYPIC TREATMENT REGIMENS FOR CHRONIC HEPATITIS C (2019) (0)
- P511 USE OF C-METHACETIN BREATH TEST (MBT) TO PREDICT CIRRHOSIS COMPLICATIONS AND MORTALITY IN PATIENTS WITH LOW MELD SCORES EVALUATED OR LISTED FOR LIVER TRANSPLANTATION (LT) (2014) (0)
- 686 EFFECTS ON PRURITUS AND SLEEP DISTURBANCE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) AFTER 1 YEAR OF TREATMENT WITH SELADELPAR, A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA AGONIST: RESULTS OF AN OPEN-LABEL PHASE 2 STUDY (2020) (0)
- Mode of transmission predicts, clinical outcome in chronic hepatitis C: An age matched study comparing injection drug users and transfusion recipients (1998) (0)
- Don’t Forget the Cameron Lesion: A Rare Cause of Obscure Gastrointestinal Bleeding (OGB): 865 (2014) (0)
- 474 A Decision Analytic Markov Model to Evaluate the Health Outcomes of Sofosbuvir for Previously Untreated Patients and Those Without Treatment Options With Chronic Hepatitis C Virus (2014) (0)
- Substantial healthcare utilization (HCU) and costs among non-alcoholic steatohepatitis (NASH) patients with comorbid diabetes mellitus (DM): Real-world analysis of 2007–2015 US Medicare data (2018) (0)
- Predicting Relapse to Pegylated Interferon and Ribavirin Therapy According to First HCV RNA Negativity: 341 (2005) (0)
- Non-Hodgkin B-Cell Lymphoma in Hepatitis C Virus Infection (2018) (0)
- A Decision Analytic Markov Model to Evaluate the Health Outcomes of Sofosbuvir for Previously Untreated Patients and Those Without Treatment Options with Chronic Hepatitis C Virus Genotype 2 Infection (2013) (0)
- Mo1473 – Seladelpar for the Treatment of Primary Biliary Cholangitis: Experience with 26 Cirrhotic Patients (2019) (0)
- 342 CLINICAL PRESENTATION OF LEAN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) ACROSS THE WORLD: DATA FROM THE GLOBAL NASH REGISTRY (2021) (0)
- RIBA-3 HCV-positive/PCR-negative patients have T cell immunity indicating prior infection (1998) (0)
- IDDF2020-ABS-0060 Impact of prior tenofovir disoproxil fumarate (TDF) treatment duration on tenofovir alafenamide (TAF) safety profile in virally suppressed chronic HBV patients switched from TDF to TAF (2020) (0)
- 35 – Hepatitis A (2018) (0)
- Effect of SVR on liver-related and all-cause hospitalization of patients with chronic HCV infection: The chronic hepatitis cohort study (CHECS), 2014-16. (2018) (0)
- PATIENT CHARACTERISTICS AND EFFICACY OF PANGENOTYPIC DIRECT-ACTING ANTIVIRAL REGIMENS AMONG A COHORT OF CHRONIC HEPATITIS C PATIENTS RECEIVING ROUTINE CLINICAL CARE IN THE US (2020) (0)
- Validity of an Automated Algorithm to Identify Cirrhosis Using Electronic Health Records in Patients with Primary Biliary Cholangitis (2020) (0)
- Hepatitis C patients with HIV co-infection demonstrate unique liver-related complications and health behaviors compared to HCV mono-infected patients (2018) (0)
- The point of care 13C-Methacetin Breath Test predicts risk of long-term liver-related death or transplantation in patients with chronic liver disease: a sensitive, noninvasive monitoring tool in clinical hepatology (2017) (0)
- Lower rates of emergency visits and hospitalizations among chronic hepatitis C patients with sustained virological response to interferon-free direct-acting antiviral therapy (2014-2018). (2022) (0)
- Evolving Screening and Vaccination Recommendations for Hepatitis B in the USA (2022) (0)
- Direct Healthcare Costs Associated with Osteoporosis and Bone Fracture in Pharmacologically Treated Chronic Hepatitis B Patients: Results of A United States Population-Based Cohort Study (2017) (0)
- Editorial: Changing trends in the US prevalence of hepatitis B core antibody provide important perspectives into future screening and vaccination strategies. (2021) (0)
- Cryotherapy for Palliation of Malignant Dysphagia: 3 (2013) (0)
- Sa1492 - HIV Co-Infection is Associated with Increased Liver Complications and Reduced Mental Health Among Patients with Chronic Hepatitis B (2018) (0)
- HEPATITIS C VIRUS AS A CO-FACTOR IN AZATHIOPRINE-INDUCED CHOLESTASIS: 594 (2004) (0)
- IDDF2020-ABS-0057 Risk of incident hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) virus-infected patients treated with tenofovir disoproxil fumarate (TDF) versus entecavir (ETV): a US administrative claims analysis (2020) (0)
- Treatment of unresectable hepatocellular carcinoma using intra-arterial yttrium-90 (TheraSphere): Report of a pilot trial (2003) (0)
- Is there still a role for liver biopsy in managing hepatitis C virus infections? (2012) (0)
- S2392 Diagnosis and Management of Spontaneous Splenorenal Shunts (2020) (0)
- Laboratory monitoring and antiviral treatment for chronic hepatitis B among routine care patients in the United States (2021) (0)
- PS2-10: Predictors of Depression and Poor Physical Health among Patients with Chronic Hepatitis C Infection: Results from the Chronic Hepatitis Cohort Study (2014) (0)
- When Treatment Is Mitigated by Adverse Events: The Economic Impact of Treatment-Associated Adverse Events in Cirrhotic Non-Responders Treated with Boceprevir or Telaprevir and Peginterferon Alpha/Ribavirin (2013) (0)
- Retroperitoneal Abscess Following EUS-Guided Celiac Plexus Block: 1529 (2014) (0)
- THU-308-More than 4 times higher healthcare costs for end-stage liver disease patients with non-alcoholic fatty liver disease/nonalcoholic steatohepatitis (2019) (0)
- Clinical Epidemiology and Molecular Biology of Hepatitis C (1993) (0)
- Health outcomes among surveyed patients infected with hepatitis C in the Chronic Hepatitis Cohort Study (CHeCS) (2017) (0)
- S3066 Interferon Therapy for Chronic Hepatitis Delta Viral Infection (2022) (0)
- Isolated Hepatitis B Core Antibody is a Frequent Serologic Profile Denoting Prior Type B Hepatitis: 400 (2009) (0)
- P16 SOF/VEL/VOX for 8 or 12 weeks results in high SVR12 rates: an integrated analysis of the POLARIS-1, POLARIS-2, POLARIS-3 AND POLARIS-4 studies (2017) (0)
- Novel Technique for Intradiverticular Advanced Adenoma Resection: 2164 (2014) (0)
- 3026 Rare Complication of Chronic Pancreatitis: Chronic Portal Vein Thrombus Causing Pre-Hepatic Portal Hypertension (2019) (0)
- Targeted Adverse Outcomes in Acute Pancreatitis are Infrequent in Non-transferred Patients: Implications for Future Research Studies: 169 (2010) (0)
- A1-4: Pragmatic and Adaptive Methods of Electronic Medical Record (EMR) Cohort Identification for Comparative Effectiveness Research (2013) (0)
- Celiac Disease Should Be Considered in Patients with Cryptogenic Cirrhosis: 831 (2008) (0)
- Mo1425 - Hepatitis C (HCV) Patients with HIV Co-Infection Demonstrate Unique Liver-Related Complications and Health Behaviors Compared to HCV Mono-Infected Patients (2018) (0)
- Hepatic Manifestations of Systemic Diseases. (2023) (0)
- Persistence of the hepatitis C viral genome in the kissing bug (Rhodnius prolixus) (2001) (0)
- Hepatitis B testing in a large cohort of U.S. hepatitis C virus-infected patients (2017) (0)
- Erratum: "R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin" (Hepatology (2008) vol. 48 (385-397) 10.1002/hep.22357) (2008) (0)
- Is there a correlation between hepatic steatosis, fibrosis, body mass index and viral levels in americans with chronic hepatitis C? (2000) (0)
- Treatment of Chronic Viral Hepatitis in Patients with Autoimmune Diseases (2002) (0)
- Reply (2014) (0)
- Aortitis in a Patient with Chronic Hepatitis C Virus Infection: 1816 (2016) (0)
- Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study (2023) (0)
- A non-invasive serum fibrosis marker panel can consistently select chronic hepatitis C patients with minimal stage (F0–F1) fibrosis from more advanced disease (F2–F4) (2003) (0)
- 1307-P: Real-World Health-Care Costs Impacted by Diabetes Mellitus (DM) among Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) Patients with Advanced Liver Diseases (AdvLD) (2019) (0)
- RISK FACTORS FOR SARS-COV-2 INFECTION AMONG PATIENTS WITH CHRONIC VIRAL HEPATITIS (2020) (0)
- P0730 : Prevalence and characteristics of hepatitis C genotypes in the chronic hepatitis cohort study (CHeCS) (2015) (0)
- 1253-P: High Health-Care Utilization (HCU) and Costs Associated with Diabetes Mellitus (DM) and Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) in Medicare Patients (2019) (0)
- LIVER Ef fi cacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid (2015) (0)
- Rising and higher healthcare-resource-utilization (HCRU) and costs of Nonalcoholic Fatty Liver Disease (NAFLD)/ Nonalcoholic Steatohepatitis (NASH) patients with advanced liver disease-a US real-world-analysis. (2019) (0)
- T.N.3 A GENOME-WIDE DNA METHYLATION STUDY IN MONOZYGOTIC TWINS DISCORDANT FOR PRIMARY BILIARY CIRRHOSIS (2010) (0)
- Utility of Historical Data Compared to Lead-in Response in Predicting Sustained Virologic Response in Non-Responders and Relapsers to Peginterferon/Ribavirin When Re-Treated With Boceprevir+Peginterferon Alfa-2B/Ribavirin (PR) (2011) (0)
- Ileal Varices Causing Massive Gastrointestinal Hemorrhage in a Cirrhotic Patient: 689 (2010) (0)
- HEPATITIS C VIRUS (HCV) PATIENTS IN A LARGE U.S. COHORT (2013) (0)
- PS2-03: Chronic Hepatitis B Testing in US-born and Foreign-born Asia Pacific Islanders of Kaiser Permanente, Hawai’i (2012) (0)
- Introducing ERCP in a Low Income Country: A Case Series From Rwanda Endoscopy Week (2018) (0)
- Reply: To PMID 23813604. (2014) (0)
- 1115 IMPACT OF HCV TREATMENT AND DISEASE SEVERITY ON HEALTH CARE COSTS IN CHRONIC HCV PATIENTS: ANALYSIS OF A LARGE US PRIVATE HEALTH INSURANCE CLAIMS DATABASE (2012) (0)
- Multifocal Splenic Steatosis in End Stage Cholestatic Liver Disease: 656 (2007) (0)
- Editorial: how widespread and serious is non‐alcoholic fatty liver disease in the real world? Authors' reply (2020) (0)
- The Benefits and Limitations of On-Site Smear Review During EUS-FNA for Pancreatic Adenocarcinoma: 236 (2009) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Stuart C. Gordon?
Stuart C. Gordon is affiliated with the following schools:
